AI Science Tracker
EN

PatchSight-ImmuneMap-LifeSpan as a unified AI framework for breast cancer diagnosis, immune profiling and prognostic prediction.

Affiliation not stated in the reviewed material · 30 Jan 2026 · medicine

Discovery

PatchSight-ImmuneMap-LifeSpan as a unified AI framework for breast cancer diagnosis, immune profiling and prognostic prediction.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: The framework reports specific breast-cancer diagnosis, TIL-detection and survival-prediction evaluations on public datasets, qualifying as task-specific retrospective validation. No prospective clinical validation or new biology is shown, and reported performance varies by dataset/task.

Technology: Methods/Results evaluate InceptionResNetV2 on BreakHis, Faster R-CNN on LYSTO and survival prediction on public datasets; test metrics include survival C-index around 0.74. These are benchmark-dataset task evaluations, not deployment evidence.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Methods/Results evaluate InceptionResNetV2 on BreakHis, Faster R-CNN on LYSTO and survival prediction on public datasets; test metrics include survival C-index around 0.74. These are benchmark-dataset task evaluations, not deployment evidence.
Limitation / still unknown
Evaluations use public retrospective datasets; performance varies by diagnostic, immune-profiling and survival task, with no prospective clinical validation or new biological finding reported.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1007/s12672-026-04491-6

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.